Isomerase is pleased to highlight the news that Abliva AB (located in Lund, Sweden and Boston, US) are moving the NV354 programme into clinical development. Isomerase supports Abliva across their preclinical and clinical projects and NV354 originated from this collaboration. Steven Moss, a co-inventor of NV354, commented ‘Abliva and Isomerase work together closely on a number of projects, with Isomerase providing chemistry and discovery support to the project team. On NV354 we worked with the Abliva team on their concept of succinate prodrugs to design a molecule that met a challenging target product profile and relied on a deep understanding of cellular metabolism. Isomerase’s contribution includes compound design, bioanalytics, compound profiling, process development and managing GMP manufacture for preclinical and clinical studies. We wish Abliva success in the further development of this asset that could have a meaningful impact on patients in an underserved area of medicine.’
Our team is uniquely placed to assist partners with all aspects of discovery and development of microbial natural products, such as leading edge synthetic biology, advanced strain improvement of microorganisms, genome sequence analysis, protein and peptide expression and isolation, small scale fermentation and process development, DSP, compound isolation, analytical development and synthetic chemistry. In addition, as required, Isomerase also manages all other aspects necessary for a commercially successful programme on behalf of partners, such as compound management and shipping, scaled manufacture and tailored drug discovery screening cascades.
We offer these capabilities underpinned by an extensive portfolio of technology IP, and the combined experience of a core technical and leadership team with a substantive track record of successful drug discovery and development collaborations with pharma and biotech companies.
We have supported numerous companies with a wide variety of microbial product and small molecule fermentation and synthetic chemistry projects, helping advance early stage concepts into valuable development programmes, and then continuing to support their progress to market with process improvement and scaled manufacture.
To find out more, visit: www.isomerase.co.uk